Precision Medicine Simplified

Introducing an innovative approach to make
management of complex disorders simple,
fast, effective, and affordable.

Going Beyond Genetics to Guide Clinical Decisions

Integrating genetic, environmental, clinical data and curated guidelines from the world’s top experts to guide earlier diagnoses and patient-specific care plans.

Currently, many complex diseases are detected too late in their progression based on symptoms that can be misleading. Ariel goes beyond symptoms using genetics to provide valuable information to clarify risk and guide a personalized approach to the early detection and treatment of complex diseases. Our reports are tailored to each patient, integrating patient reported outcomes, environmental and medical history into the interpretation of the genetic data.

 

Curated Single Nucleotide Polymorphism (SNP) Genotyping

Ariel uses pre-defined SNPs with known effects so that the impact can immediately be integrated into complex disease models and the analysis process is not slowed by exploring the possible impact of rare genetic variants of unknown significance (VUS). This approach optimizes speed and efficiency of the system as a screening tool with the recognition that additional genetic testing may be required to discover rare or complex genetic variants that are not commonly part of established disease models.

 

Order Remotely

Ariel’s SNaP-Shot™ panels can be ordered remotely for patients and testing can be done in the privacy of their home using a cheek swab test. Ariel’s tests can be ordered by a licensed provider and the direct pay model ensures complete transparency into pricing.

Ariel expertise

What ARIEL offers you, the physician:

Unravel complex conditions with the help of integration of health information backed by genetics. Ariel uses comprehensive genetic testing to understand and interpret risk factors for each patient. In addition to traditional Mendelian variants, Ariel reports disease modifying and complex genetic variants, some of which can influence biomarker interpretation and drug response.

Our platform provides you with clinical considerations according to guidelines Our forward thinking team monitors research on re-classification of variants or discovery of new variants and integrates this new information into our platform to push relevant updates to you for each patient over time.

Our reports are tailored to each patient, integrating patient reported outcomes, environmental and medical history (including family history) into the interpretation of their genetic data.

Our platform uses high quality array technology in a CLIA-certified laboratory with layers of QC to confirm accuracy for reporting.

How It Works

Ariel Precision Medicine ADVANCE cloud-based clinical decision support platform
Play Video

Targeted SNP Array Panels SNaP-Shot™

SNaP-Shot™ is a Precision Medicine tool. SNaP-Shot™ Reports are based on the analysis of limited sets of patient genetic (DNA) variants relevant to signs and symptoms of human disease. The data is transformed into clinically relevant information by combining an individual’s genetic information with their relevant health histories, lifestyle information and biomarkers using disease models linked to expert clinical decision support (CDS) systems. This new patient-specific information is designed

to help clinicians with (a) risk assessment, (b) differential diagnosis, (c) treatment selection, (d) prognosis and/or (e) management plans. HIPAA-compliant Reports are available to healthcare providers and the patient. Reports can be updated over time as the patient’s condition and biomarkers change, as new information becomes available or new medical advances are published.

Pancreatitis SNaP-Shot™

A genotyping-array test of over 60 genetic variants related to the risk for pancreatitis, celiac disease, gallstones, and hypertriglyceridemia. Also includes a polygenic risk score (PRS) for type 2 diabetes mellitus.

ABCG8, APOA5, APOB, CASR, CFTR, CLDN2, CTRC, GGT1, HLA-DQA1, HLA-DQB1, LPL, PRSS1, PRSS1-PRSS2, SLC10A2, SLC26A9 and SPINK1.

Genetic testing for pancreatitis is recommended for individuals with pancreatitis that meet one or more of the following criteria:
  • An unexplained episode of acute pancreatitis in childhood
  • Recurrent acute or chronic pancreatitis without a known cause, particularly with early-onset
  • A family history of pancreatitis of unknown cause
  • A family history of pancreatitis with an established genetic cause
  • Additional symptoms consistent with a genetic disorder that includes pancreatitis as a symptom, such as cystic fibrosis or a CFTR-related disorder
  • Additionally, individuals that meet any of the following criteria may also benefit from genetic testing:
    • One or more attacks (or suspected attacks) of acute pancreatitis
    • Abdominal pain after eating, chronic diarrhea, abnormal findings on a CT or MRI scan, or an abnormal laboratory test related to the pancreas
Genetic testing for pancreatitis is recommended for individuals with pancreatitis that meet one or more of the following criteria:
  • An unexplained episode of acute pancreatitis in childhood
  • Recurrent acute or chronic pancreatitis without a known cause, particularly with early-onset
  • A family history of pancreatitis of unknown cause
  • A family history of pancreatitis with an established genetic cause
  • Additional symptoms consistent with a genetic disorder that includes pancreatitis as a symptom, such as cystic fibrosis or a CFTR-related disorder
  • Additionally, individuals that meet any of the following criteria may also benefit from genetic testing:
    • One or more attacks (or suspected attacks) of acute pancreatitis
    • Abdominal pain after eating, chronic diarrhea, abnormal findings on a CT or MRI scan, or an abnormal laboratory test related to the pancreas
$299 for Pancreatitis SNaP-Shot™

Pancreatic Cancer Biomarker and Risk SNaP-Shot™

A screening test that identifies high-risk individuals (HRI) who may benefit from pancreatic cancer (PC) surveillance by:

(A) Determining genetic risk factors and incorporating these to their risk status and cancer biomarker profile.

(B) Improving interpretation of new- onset diabetes (NOD) caused by PC.  1, 2

(C) Assessing CA 19-9-related genetic variants (FUT2/FUT3) to help interpret laboratory results.

  • FUT2 and FUT3:to identify the likely CA 19-9 expression level of a patient 3, 4
  • PC Polygenic Risk Score: 49 genetic variants are used to identify patients with higher of risk [RV1] [DW2] [DW3]  for pancreatic ductal adenocarcinoma (PDAC). 2
  • Type 2 diabetes mellitus (T2DM) Polygenetic Risk Score: 59 genetic variants are utilized to identify patients in the lower risk for T2DM [RV4] [DW5] (potentially more likely to have NOD from PC) 5
Age > 50 years, Plus:
  • Family history of PC or other cancers but does not meet criteria as an HRI for screening. 6
  • Known risk factors for PDAC: smokinger, history of acute or chronic pancreatitis (> 2 years ago), diabetes mellitus (> 3 years ago), obesity. 7-9
  • Worrisome clinical features: New- onset diabetes (NOD), recent acute or chronic pancreatitis, unexplained weight loss, characteristic abdominal/back pain, new maldigestion symptoms, obstructive jaundice, pancreas imaging findings of developing cyst with abnormal features or > 3 cm, dilated pancreatic duct (c/w IPMN), other features. 2, 10-12
  • Biomarkers of PDAC: elevated CA 19-9 levels or other. 3, 4, 13
  • Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology 2018;155:730-739 e3.
  • Sharma S, Tapper WJ, Collins A, Hamady ZZR. Predicting Pancreatic Cancer in the UK Biobank Cohort Using Polygenic Risk Scores and Diabetes Mellitus. Gastroenterology 2022;162:1665-1674 e2.
  • Abe T, Koi C, Kohi S, et al. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol 2020;18:1161-1169 e5.
  • Dbouk M, Abe T, Koi C, et al. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges. Clin Cancer Res 2023;29:4178-4185.
  • Goodarzi MO, Nagpal T, Greer P, et al. Genetic Risk Score in Diabetes Associated With Chronic Pancreatitis Versus Type 2 Diabetes Mellitus. Clin Transl Gastroenterol 2019;10:e00057.
  • Sawhney MS, Calderwood AH, Thosani NC, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc 2022;95:817-826.
  • Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol 2015;44:186-98.
  • Cho J, Scragg R, Petrov MS. Postpancreatitis Diabetes Confers Higher Risk for Pancreatic Cancer Than Type 2 Diabetes: Results From a Nationwide Cancer Registry. Diabetes Care 2020.
  • Yuan C, Kim J, Wang QL, et al. The age-dependent association of risk factors with pancreatic cancer. Ann Oncol 2022;33:693-701.
  • Placido D, Yuan B, Hjaltelin JX, et al. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Nat Med 2023;29:1113-1122.
  • Khan S, Safarudin RF, Kupec JT. Validation of the ENDPAC model: Identifying new-onset diabetics at risk of pancreatic cancer. Pancreatology 2021;21:550- 555.
  • Munigala S, Subramaniam DS, Subramaniam DP, et al. Incidence and Risk of Pancreatic Cancer in Patients with a New Diagnosis of Chronic Pancreatitis. Dig Dis Sci 2022;67:708-715.
  • Whitcomb DC, Oranburg TD, Vallente R, Brand RE. SMART Medical Review: CA 19-9 and pancreatic ductal adenocarcinoma (PDAC).: CA 19-9 and Pancreatic Cancer. SMART-MD Journal of Precision Medicine 2024;1:14-27.
Pancreatic Cancer Biomarker and Risk SNaP-Shot TM is $299. Pharmacogenomic SNaP-Shot can be added on for $150.

Pharmacogenomics SNaP-Shot™

An affordable clinical pharmacogenomics test and interpretation service that helps identify how patients are likely to respond to a medication or a specific medication dose. By analyzing genetic variants from 27 genes, Pharmacogenomics SNaP-Shot™ provides genetic insights to match appropriate medication and dosage to patients. It can also help avoid adverse drug events that are associated with specific genetic variants. Pharmacogenomics SNaP-Shot™ covers more than 125 medications used to treat a wide range of medical conditions.

ABCG2, BCHE, CACNA1S, COMT, CYP2B6, CYP2C, CYP2C19, CYP2C9, CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-A,
HLA-B, HLA-DQA1, HLA-DRB1, MT-RNR1, MTHFR, NAT1, NAT2,
NUDT15, OPRM1, RYR1, SLCO1B1, TPMT, UGT1A1, & VKORC1

  • Provide guidance before a new medication is prescribed.
  • Patient history of poor drug response.
  • Patient history of adverse drug reactions.
  • Patient prescribed multiple medications.
  • Family history of poor response to medications.

Please note:

  • Pharmacogenomics SNaP-Shot™ (PGx) testing is not available for all drugs.
  • Pharmacogenomics SNaP-Shot™ (PGx)  does not test for all known or future Pharmacogenomics SNaP-Shot™ (PGx) associations.
  • Current medications should not be changed based on PGx results without consulting with the prescriber.
  1. FDA (2020). Table of Pharmacogenetic Associations.
  2. Johnson JA, et al. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenomics-Guided Wafarin Dosing: 2017 Update. Clinical Pharmacology and Therapeutics.
  3. Moriyama B, et al. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clinical Pharmacology and Therapeutics.
  4. Scott SA, et al. (2013). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Clinical Pharmacology and Therapeutics.
$249 for Pharmacogenomics SNaP-Shot™

Ariel's Testing Process is Simple!

order-icon

Place an order

Place an order using our secure portal.

Registration-icon

Patient Registration

After the order has been placed, your patient will receive an email invitation to complete registration for testing.

dna-collection

DNA Collection

A DNA collection kit will be shipped to your patient’s home. They will collect their DNA sample and send it back to us for analysis.

results-icon

Receive Results

You will receive an email notification letting you know that the genetic report is ready to review. You will be able to review the report online.

Order A SNaP-Shot™ Genetic Panel To Start Personalizing Your Patient's Care Plan Today!

Understand Your Report

Play Video

Frequently Asked Questions

An emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.

For Pancreatitis SNaP-Shot™:

Identifying the underlying biological causes of your patient’s pancreatitis symptoms can help direct therapy and guide medical management specific to the patient’s disease process. For example, genetic conditions such as hereditary pancreatitis and cystic fibrosis can both increase the risk of pancreatitis, but involve different treatments and clinical considerations. Early detection of the cause or causes of the disease process may prevent extensive diagnostic evaluations, delayed diagnosis and more severe end-stage disease.

 

For Pharmacogenomics SNaP-Shot™:

A person’s genetic variants can impact how they will respond to medications (pharmacogenomics, PGx). PGx data can help you identify patients who are more likely to respond to a medication or a specific medication dose. It can also help patients  avoid adverse drug events that are associated with specific genetic variants.

 

For Pancreatic Cancer SNaP-Shot™:

A genotype based test to screen for risk and support the early detection of pancreatic cancer (combining clinical, environmental and genetic risk factors such as polygenic risk scores and familial cancer variants to determine current risk of an occult cancer and to calibrate the level of CA 19-9 and CEA as biomarkers based on FUT 2/FUT3 genetics), and support management in the event of the early diagnosis of pancreatic cancer including genetic effects on biomarker levels (CA 19-9 and CEA), chemotherapy pharmacogenetics (PGx e.g. 5-FU, Folfirinox) pain and nausea PGx.”

SNaP-Shot™ genetic analysis goes beyond genetics to incorporate genetic testing, patient medical and family history, patient biomarkers, and up-to-date management considerations to provide a comprehensive and actionable precision medicine report.

 

Pancreatitis SNaP-Shot™ tests for predisposition to both Mendelian (monogenic) and complex (multifactorial) forms of disease. A minority of pancreatitis patients have a monogenic cause of disease. Therefore, testing for predisposing risk variants in addition to monogenic disease variants assures a complete picture of known genetic predisposition.

 

Pancreatic Cancer SNap-Shot™: A genotype based test to screen for risk and support the early detection of pancreatic cancer (combining clinical, environmental and genetic risk factors such as polygenic risk scores and familial cancer variants to determine current risk of an occult cancer and to calibrate the level of CA 19-9 and CEA as biomarkers based on FUT 2/FUT3 genetics), and support management in the event of the early diagnosis of pancreatic cancer including genetic effects on biomarker levels (CA 19-9 and CEA), chemotherapy pharmacogenetics (PGx e.g. 5-FU, Folfirinox) pain and nausea PGx.”

 

Pharmacogenomics SNaP-Shot™: is an affordable clinical pharmacogenomics (PGx) test and interpretation service that helps identify how patients are likely to respond to a medication or a specific medication dose. By analyzing genetic variants from 27 genes, Ariel SNaP-Shot™ provides genetic insights to match appropriate medication and dosage to patients. It can also help avoid adverse drug events that are associated with specific genetic variants. Pharmacogenomics SNaP-Shot™ covers more than 125 medications used to treat a wide range of medical conditions.

Please contact info@arielmedicine.com or 844-692-7435 to request a sample report.

Ariel is committed to a streamlined and convenient ordering and results disclosure process:

  1. SNaP-Shot™ is a clinician-ordered test. To begin, create an account through the easy-to-use and secure Ariel online provider portal to place the order.
  2. Once the order is placed, your patient will receive an email from Ariel inviting them to register online, sign consent forms, pay for testing, access help resources, and complete their health profile.
  3. A cheek swab kit will be mailed to your patient’s home. The patient will be provided with instructions to swab the inside of their cheek and return their DNA sample by mail.

Please tell your patient to expect an email from Ariel. Once you place an order in the secure portal, Ariel will send your patient a ‘Welcome’ email with a link to Ariel’s secure patient portal to register. The patient can follow the instructions in their email to register in Ariel’s online portal, provide payment information, complete the informed consents, and their registration profile. Once the registration forms are complete, Ariel ships a DNA testing kit to the patient’s preferred shipping address. The Ariel test kit includes all materials and resources necessary to support the patient in collecting and returning their sample for testing.

No, Ariel does not offer genetic counseling services.

The turnaround time for test results is 4-6 weeks.

  • Pancreatic Cancer SNaP-Shot™ $299
  • Pancreatitis SNaP-Shot™ $299.
  • Pharmacogenomics SNaP-Shot™ $249.

Direct pay model overcomes the traditional barriers of prior authorizations, medical record requests, letters of medical necessity and insurance denials.

Payment can be made by credit card or check. Payment is accessible through the patient’s health profile. Ariel customer support is available for any questions. Please call (844) 692-7435.
Ariel upholds the highest security measures to help ensure any personal information remains safe. We do not store cardholder data (“CHD”) in any cases.
Yes, Ariel provides payment plans for patients who may not be able to afford to pay for their SNaP-Shot genetic test all at once. Please call Ariel’s Customer Service at (844) 692-7435 to learn more about this option.
Don’t hesitate to reach out to Ariel’s Customer Service department, Monday through Friday, 8 a.m. – 8 p.m. EST at (844) 692-7435 or via info@arielmedicine.com.

Still Have Questions?

If you still have questions, we would love to answer them. Request a quick call with our team and we’ll be in touch.